ACCESSWIRE

SHAREHOLDER ALERT: Potential Recovery for Masimo Corporation (MASI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 17, 2023 / If you suffered a loss on your Masimo Corporation (NASDAQ:MASI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/masimo-lawsuit-submission-form?prid=48555&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Masimo Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 28, 2023 and July 17, 2023.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Masimo's revenue and sales for the second quarter of fiscal 2023 and expected revenue for the full-year 2023. Defendants' statements included, among other things, Masimo's ability to deliver clinically proven new products to the healthcare markets thereby supporting defendants' decision to forecast revenue of $550 million to $565 million for the quarter and increase its earnings-per-share estimates to between $3.59 per share and $3.69 per share. Defendants' statements in this regard prompted an immediate and dramatic increase in the price of Masimo's common stock. From a closing price of $167.31 per share on February 28, 2023 at the start of the Class Period, Masimo's stock price climbed to $184.97 per share the following day on March 1, 2023 on unusually high volume. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts. On July 17, 2023 Masimo issued a press release announcing its second quarter 2023 earnings. Defendants announced lower than expected revenue for the second quarter of fiscal 2023 and preliminarily decreased full-year revenue estimates for both healthcare and non-healthcare segments. On this news, the price of Masimo's common stock declined dramatically. From a closing market price of $147.16 per share on July 17, 2023, Masimo's stock price fell to $117.73 per share on July 18, 2023, a decline of nearly 20% in the span of just a single day.

WHAT'S NEXT? If you suffered a loss in Masimo stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/masimo-lawsuit-submission-form?prid=48555&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/784910/shareholder-alert-potential-recovery-for-masimo-corporation-masi-investors-affected-by-stock-drop-levi-korsinsky-pursuing-class-action-lawsuit

NOTE: This content is not written by or endorsed by "WSPA", its advertisers, or Nexstar Media Inc.

For inquiries or corrections to Press Releases, please reach out to Accesswire.